MedTrace Logo

Nutraceutical on Hyperuricemia

NCT04161872 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2020-11-10

No results posted yet for this study

Summary

The aim of this study will be to evaluate if a nutraceutical containing quercetin, rutin, bromelain and L-carnosine (Uricemin®) can reduce uric acid levels in subjects with values between ≥ 6 and \< 7 mg/dl after 3 months of therapy.

Conditions

  • Hyperuricemia

Interventions

DRUG

Uricemin

Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • University of Pavia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-11-30
Completion
2019-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161872 on ClinicalTrials.gov